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Abstract
Introduction: The aim of this work was to evaluate the role of human plasma prekallikrein assembly and processing in cells
and to determine whether proteoglycans, along with high molecular weight kininogen (H-kininogen), influence this
interaction.
Methods:We used the endothelial cell line ECV304 and the epithelial cell lines CHO-K1 (wild type) and CHO-745 (deficient in
proteoglycans). Prekallikrein endocytosis was studied using confocal microscopy, and prekallikrein cleavage/activation was
determined by immunoblotting using an antibody directed to the prekallikrein sequence C364TTKTSTR371 and an antibody
directed to the entire H-kininogen molecule.
Results: At 37uC, prekallikrein endocytosis was assessed in the absence and presence of exogenously applied H-kininogen
and found to be 1,418.460.010 and 1,070.360.001 pixels/cell, respectively, for ECV304 and 1,319.160.003 and 631.360.001
pixels/cell, respectively, for CHO-K1. No prekallikrein internalization was observed in CHO-745 in either condition.
Prekallikrein colocalized with LysoTracker in the absence and presence of exogenous H-kininogen at levels of 76.0% and
88.5%, respectively, for ECV304 and at levels of 40.7% and 57.0%, respectively, for CHO-K1. After assembly on the cell
surface, a plasma kallikrein fragment of 53 kDa was predominant in the incubation buffer of all the cell lines studied,
indicating specific proteolysis; plasma kallikrein fragments of 48–44 kDa and 34–32 kDa were also detected in the
incubation buffer, indicating non-specific cleavage. Bradykinin free H-kininogen internalization was not detected in CHO-K1
or CHO-745 cells at 37uC.
Conclusion: The prekallikrein interaction with the cell surface is temperature-dependent and independent of exogenously
applied H-kininogen, which results in prekallikrein endocytosis promoted by proteoglycans. Prekallikrein proteolysis/
activation is influenced by H-kininogen/glycosaminoglycans assembly and controls plasma kallikrein activity.
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Introduction
The plasma kallikrein/kinin system, which comprises the
contact system proteins plasma prekallikrein, high molecular
weight kininogen (H-kininogen) and Factor (F)XII is a physiologic
mediator of vascular biology and inflammatory reactions. Human
plasma kallikrein is a protease that was first found to affect
hemostasis by amplifying FXII activation and inflammation by H-
kininogen hydrolysis and bradykinin release. Plasma kallikrein also
affects fibrinolysis and plasmin formation by single-chain uroki-
nase plasminogen activation or plasminogen cleavage [1]. Other
functions have also been attributed to plasma kallikrein, such as
the activation of the plasminogen cascade in adipogenesis and
mammary gland development [2], [3], tissue repair and angio-
genesis through the hepatocyte growth factor/c-Met activation
pathway [4], [5], and hepatic regeneration by latent TGF-b
activation [6].
The plasma kallikrein-kinin system proteins have been impli-
cated in the pathogenesis of inflammation, hypertension, endo-
toxemia, coagulopathy, angiogenesis, epithelial cell apoptosis,
adipocyte differentiation, and stromal remodeling and the
interaction with cell surface could be a mechanism for controlling
their activities [7].
The H-kininogen interaction with the surfaces of endothelial
cells is mediated by a protein complex involving the globular head
domains of the complement component C1q, the urokinase
plasminogen activator receptor, and cytokeratin 1 [8]. Proteogly-
cans may function as binding sites for H-kininogen and promote
its internalization [9], [10], [11] [12]. Heparin released from
activated mast cells triggers edema during allergic reactions and
inflammatory diseases by activating the coagulation intrinsic
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pathway [13]. It is well known that H-kininogen is a potent
proangiogenic molecule through bradykinin release. On the other
hand, plasma kallikrein cleaved H-kininogen (bradykinin free H-
kininogen) is a potent antiangiogenic agent [14]. Taken together,
besides regulating VEGF-VEGFR signaling system [15], [16], [17]
cell surface proteoglycans can also regulate angiogenesis by
modulating plasma kallikrein-kinin system activity.
In our previous work, we showed that human plasma
prekallikrein, the zymogen form of plasma kallikrein, specifically
and reversibly binds to human umbilical vein endothelial cells
(HUVECs) in the presence or absence of exogenously applied H-
kininogen. The cell-associated plasma prekallikrein is then rapidly
activated to plasma kallikrein independently of exogenous FXII
[18]. Because cell-bound H-kininogen is cleaved by mature plasma
kallikrein on HUVECs, bradykinin can be released near the
endothelium where it exerts its functions and bradykinin free H-
kininogen can be generated [19].
Cerf et al. [20] observed intense labeling for plasma kallikrein in
endothelial cells, foamy macrophages, inflammatory cells and
fibroblasts within the thickened intima of the plaque as well as in
smooth muscle cells of the underlying tunica media. The authors
suggested the possibility of plasma kallikrein induction by
atheromatous disease. Fink et al. [21] demonstrated prekallikrein
or plasma kallikrein localization in various human tissues including
single cells of the distal tubules in nephrons, hepatic epithelial cells,
cells of the pancreatic islet of Langerhans, interstitial Leydig cells
of the testes, follicular and thecal granulosa cells of the ovary, the
parotid gland, the esophagus, skin, the respiratory tract, the
prostate and the breast. In addition, Chee et al. [22] found plasma
kallikrein in the cytoplasm and demonstrated nuclear labeling of
malignant mesothelioma cells.
Plasma kallikrein-kinin proteins have also been found on the
surface and in the extracellular matrix of endothelial cells from line
ECV304 [23], vascular smooth muscle cells [24], immortalized
human EA.hy926 endothelial cells [25], lung epithelial cells [26]
and endothelial cells from a line derived from rabbit aorta RAECs
[27]. Little is known regarding the mechanisms of plasma
prekallikrein interactions with cells. The direct prekallikrein
interaction with vascular smooth muscle cells has shown possible
prekallikrein activation in the absence of an exogenous source of
H-kininogen [28].
In the present work, we examined prekallikrein assembly and
processing on cells and analyzed whether glycosaminoglycans
(GAGs), along with H-kininogen, influence this interaction. We
used the vascular cell line, ECV304, as our endothelial cell model,
and exogenous prekallikrein was internalized either in the absence
or presence of exogenously applied H-kininogen. We used wild-
type Chinese hamster ovarian cells (CHO-K1) and mutant CHO
cells deficient in PG biosynthesis (CHO-745). We found that
prekallikrein is taken up and directed to endosomes/lysosomes and
that this endocytosis process is mediated by GAGs. In addition,
prekallikrein may be cleaved in the presence or absence of GAGs.
Therefore, prekallikrein activation while in contact with H-
kininogen on the cell surface is influenced by GAGs.
Materials and Methods
Material
All chemicals obtained from commercial sources were of the
best grade available. The biotinylation kit (NHS-LC-Biotin),
Immunopure streptavidin horseradish peroxidase conjugated
(SA-HRP), SuperSignal West Pico Chemiluminescent Substrate
and the Dylight 659 Protein Labeling kit were purchased from
Pierce Biotechnology Inc. (Rockford, IL, USA). Prekallikrein and
H-kininogen were purchased from EMD Biosciences, Inc. (La
Jolla, CA,USA); bradykinin free H-kininogen was purchased from
Enzyme Research Laboratories (South Bend, IN, USA). Lyso
Tracker (LT) Red DND-99 and Green and 49-6-diamidino-2-
phenylindole dihydrochloride (DAPI) were obtained from Molec-
ular Probes/Invitrogen Detection Technologies (Eugene, OR,
USA). Prestained Broad Range or Low Range molecular weight
standards were purchased from Bio-Rad Laboratories Ltd.
(Hercules, CA, USA). Membrane Immobilon-P transfer mem-
brane (PVDF) was obtained from Millipore Corporation (Billerica,
MA, USA). Fluoromont-G was purchased from Electron Micros-
copy Sciences (Hatfield, PA, USA). FITC-conjugated streptavidin
was obtained from Jackson ImmunoResearch Laboratories Inc.
(West Grove, PA, USA). Rabbit anti-human plasma kallikrein IgG
(U-691.10) was produced by the commercial service Eurogentec
(Lie`ge, Belgium) and goat anti-rabbit IgG peroxidase conjugated
was obtained from Sigma-Aldrich Co. (St. Louis, MO, USA).
Rabbit anti-human H-kininogen IgG was produced following the
protocol established by our group [29] and the serum was purified
on Immobilized Protein A obtained from Thermo Scientific,
Rockford, IL, USA). Plasma kallikrein was purified in our
laboratory following a previously described protocol [30].
Cell lines and culture conditions
All cell lines used in this study were approved by the Ethics
Committee on Research of EPM/UNIFESP (CEP 1207/10).
ECV304, a cell line established from primary culture of HUVECs
[31], [32], was purchased from American Type Culture Collection
(ATCC). The epithelial cell lines CHO-K1 and CHO-745 (the
mutant deficient in xylosyltransferase) [33] were gifts from Dr.
Jeffrey D. Esko (Department of Cellular and Molecular Medicine,
Glycobiology Research & Training Center, University of Califor-
nia). All cell lines were cultured in a humidified incubator
containing 2.5% CO2 at 37uC and subcultured in Ham F-12
nutrient mixture medium supplemented with 10% (v/v) heat-
inactivated fetal calf serum containing 10 U penicillin and 10 mg/
ml streptomycin and grown to confluence on 60 mm dishes.
Biotinylation of prekallikrein and labeling of bradykinin
free H-kininogen with a fluorescent dye
Prekallikrein was biotinylated (biotin-prekallikrein) as previously
reported [18], and Dylight 659-bradykinin free H-kininogen was
prepared following the manufacturer’s instructions. After labeling,
the remaining free fluorescent dye was eliminated by gel filtration
in a PD-10 column obtained from GE Healthcare UK Ltd. The
degree of labeling was estimated by absorbance measurements as
indicated by the dye manufacturer.
Immunocytochemistry
Cells were cultured on 13.0 mm diameter glass coverslips
(56103 cells/coverslip) in 24 well plates for 2 days. In the analysis
of prekallikrein internalization, the medium was removed, the cells
were washed five times with incubation buffer (Ham F-12 medium
without serum containing 50 mM Zn2+), and LT Red DND-99
(0.5 mM diluted in incubation buffer) was added for 20 min at
37uC for labeling the endocytic compartments. In the experiments
performed at 4uC, after the incubation with LT Red, the cells were
maintained at 4uC for an additional 30 min. After this step, the
cells were washed three times with incubation buffer and
incubated with H-kininogen (100 nM) or biotin-prekallikrein
(100 nM) at 4uC or 37uC. The unbound H-kininogen was
removed by washing the cells three times with incubation buffer,
and then the cells were incubated with biotin-prekallikrein
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(100 nM). Biotin-prekallikrein was removed by aspiration, and the
cells were washed with 10 mM sodium phosphate and 150 mM
NaCl at pH 7.4 (PBS) and fixed with 2% (v/v) paraformaldehyde
in PBS (pH 7.4) for 20 min at room temperature. The cells were
washed four times with PBS and once with PBS containing 0.1 M
glycine. They were then permeabilized with PBS containing 1%
(w/v) BSA and 0.01% (w/v) saponin for 15 min at room
temperature. After this step, the cells were washed with PBS and
incubated with FITC-conjugated streptavidin [5 mg/ml PBS
containing 0.01% (w/v) saponin] for 1 h at room temperature.
After washing, the cells were incubated with DAPI (2 mg/ml) in
PBS containing 0.01% (w/v) saponin for 20 min at room
temperature. The cells were washed and mounted in Fluoro-
mount-G diluted in PBS (2:1, v/v) and examined using a scanning
confocal microscope. Each figure shown in the results section
corresponds to the best of two experiments.
Time-lapse confocal fluorescence images taken under a confocal
laser scanning microscope were used to examine the cellular
trafficking of bradykinin free H-kininogen (5–30 min). For
imaging, living CHO cells grown on coverslips were washed with
incubation buffer and pre-incubated with 0.5 mM LT Green
DND-99 diluted in incubation buffer at 37uC for 20 min for
labeling the endocytic compartments. The cells were then washed
with incubation buffer and incubated with Dylight 659-bradykinin
free H-kininogen (200 nM) diluted in incubation buffer. The
fluorescent signals of LT Green DND-99 and Dylight 659-
bradykinin free H-kininogen (red) as well as the phase contrast
micrographs were monitored in real time at 37uC with a confocal
laser scanning microscope every 5 min. The labeled molecules in
acidic compartments were analyzed using an inverted confocal
laser-scanning microscope (Zeiss LSM-510, Carl Zeiss, Jena,
Germany). FITC-streptavidin and LT Green were visualized
under a 488-nm excitation from a CW Argon ion laser and its
emission was detected at 490-550 nm (green channel). LT Red
and Dylight 659 were observed with HeNe2 laser with excitation
at 633 nm and fluorescence emission was detected at 640–670 nm
(red channel). Nuclear compartments were stained with DAPI and
visualized under 359-nm excitation from multiphoton and its
emission was detected at 450–470 nm. Cells were also imaged by
differential interference contrast microscopy (DIC), using a HeNe2
laser at 633 nm. False color fluorescent images and transmitted
light images (512 6 512 pixels) were stored, quantified and
managed using the resident LSM Image Browser software (Carl
Zeiss, Jena, Germany). This allowed fluorescence intensity profiles
and colocalization rates to be measured, thereby providing mean
(6SD) intensity values for green and red emission channels of each
image.
Prekallikrein processing after assembly in different cell
lines
Experiments were performed to analyze whether the prekallik-
rein that assembled on the cell surface, with or without exogenous
H-kininogen, was processed. Cells grown in 96 microtiter plate
wells were incubated with H-kininogen (100 nM) or prekallikrein
(100 nM) in incubation buffer at 37uC for 1 h (ECV304) or
30 min (CHO cells), and unbound H-kininogen was removed by
aspiration. The cells were then incubated at 37uC with
prekallikrein (100 nM), and the incubation buffer from four
replicates of each time point (total volume of 400 ml) containing
the unbound prekallikrein was combined and lyophilized; the cells
were washed with PBS and solubilized by adding electrophoresis
sample buffer (10 ml) containing 3% (v/v) b-mercaptoethanol. The
replicate samples were combined (total volume of 40 ml), boiled,
separated by SDS-PAGE [13% (v/v)], electroblotted onto PVDF
membrane and blocked with PBS containing 0.01% (v/v) Tween
20 and 5% (w/v) non-fat milk. Anti-H-kininogen or anti-plasma
kallikrein (U-691.10) directed to the prekallikrein sequence
C364TTKTSTR371, which is exposed after prekallikrein cleavage
and activation [21], was added, and the complexes were detected
by goat anti-rabbit IgG peroxidase (HRP) conjugated. The
antigen/primary antibody/secondary antibody-HRP complexes
were detected using SuperSignal substrate. Each figure shown
corresponds to the best experiment among at least two replicates.
Results
Biotin-prekallikrein endocytosis is mediated by
proteoglycans
The interaction between biotin-prekallikrein and ECV304 cells
was investigated with and without exogenous H-kininogen. For
ECV304 at 37uC, Figure 1 (A–C) shows internalization without H-
kininogen (1,418.460.010 pixels/cell; 76.0% prekallikrein coloca-
lized with LT), and Figure 1 (D–F) shows prekallikrein internal-
ization with H-kininogen (1,070.360.001 pixels/cell; 88.5%
prekallikrein colocalized with LT). The experiments were also
performed at 4uC to prevent endocytosis, and Figure 1 (G–I)
shows almost no prekallikrein internalization without H-kininogen
(124.060.0 pixels/cell; 90.3% prekallikrein colocalized with LT).
Similarly, Figure 1 (J–L) shows no prekallikrein internalization
with H-kininogen (69.060.001 pixels/cell; 93.7% colocalized with
LT). Interestingly, prekallikrein was internalized into ECV304
cells and colocalized with LT in acidic endosomal vesicles
regardless of the presence of H-kininogen.
Because heparan sulfate and chondroitin sulfate proteoglycans
accumulate with H-kininogen on the cell surface [9], [10] and
because H-kininogen internalization is mediated by heparan
sulfate [12], we examined the possibility that prekallikrein
endocytosis is mediated by proteoglycans using the cell lines
CHO-K1 and CHO-745.
At 37uC, prekallikrein was internalized without H-kininogen in
the CHO-K1 line (Figure 2 A–C) (1,319.160.003 pixels/cell;
40.7% of prekallikrein colocalized with LT); nevertheless, pre-
kallikrein internalization was lower with H-kininogen
(631.360.001 pixels/cell; 57.0% prekallikrein colocalized with
LT) (Figure 2 D–F). The experiments performed at 4uC with
CHO-K1 confirmed that prekallikrein endocytosis depends on
temperature because no prekallikrein was detected inside the cells
(0.060.001 pixels/cell) with and without exogenous H-kininogen
Figures 2 (G–L).
The experiments performed using CHO-745 cells at 37uC show
that both without and with exogenous H-kininogen, no pre-
kallikrein internalization occurs (0.760.002 and 1.660.003
pixels/cell, respectively) (Figure 3 (A–F)); CHO-745 cells at 4uC
also show no prekallikrein uptake with or without H-kininogen
(0.860.001 and 4.460.001 pixels/cell, respectively) (Figure 3 (G–
L)).
Prekallikrein activation and H-kininogen processing after
assembly in various cell lines
GAGs participate in a variety of biological processes including
cell-matrix interactions and the activation of chemokines, enzymes
and growth factors [34]. We analyzed prekallikrein activation
during its uptake and endocytosis at 37uC in the absence and
presence of exogenous H-kininogen using the antibody U691.10 to
detect fragments that contain the sequence C364TTKTSTR371,
which is present in zymogen prekallikrein. This sequence
represents the C-terminal end of the heavy chain of plasma
Plasma Prekallikrein and Cell Surface Interaction
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kallikrein, which is newly formed upon activation of prekallikrein
by cleavage of the R371-I372 peptide bond [1], [21].
In ECV304 cells (Figure 4), prekallikrein cleavage was detected
from the cell surface samples with H-kininogen (Figure 4A), as a
53 kDa fragment appeared after a 15 min incubation. This band
remained over time and may correspond to the plasma kallikrein
heavy chain, indicating prekallikrein proteolysis. Without H-
kininogen (Figure 4B), no plasma kallikrein fragments were
detected, and the results were very similar to those of experiments
performed with HUVECs [18]. The supernatants of the samples
with (Figure 4C) and without (Figure 4D) H-kininogen at the cell
surface resulted in fragments of 53 kDa and smaller, indicating
prekallikrein proteolysis.
In CHO-K1 cells, either with or without exogenous H-
kininogen (Figure 5), no bands were detected over time from the
cell surface samples (Figures 5A and 5B). However, in the
supernatants of the samples, a 53 kDa fragment can be seen from
15 min to 2 h of incubation with (Figure 5C) and without
(Figure 5D) H-kininogen. Although the CHO-745 cells did not
internalize prekallikrein, its structure was analyzed after H-
Figure 1. Endocytosis of biotin-prekallikrein by ECV304 cells. ECV304 cells were grown on cover slips, and the lysosomes/endosomes were
labeled with 0.5 mM LT Red DND-99 in incubation buffer for 20 min at 37uC. They were treated with or without H-kininogen (100 nM, unlabelled) for
1 h and then treated with biotin-prekallikrein (100 nM) for 1 h at 37uC. The cells were incubated with FITC-conjugated streptavidin (green).
Alternatively, after labeling with 0.5 mM LT Red DND-99 at 37uC, the cells were maintained at 4uC and then treated with or without H-kininogen
(100 nM, unlabelled) for 1 h and with biotin-prekallikrein (100 nM) for 1 h at 4uC. Biotin-prekallikrein (green) endocytosis and intracellular localization
are indicated by their colocalization with acidic vesicles previously labeled with LT Red DND-99 (red) and were analyzed by confocal fluorescence
microscopy. Normal endocytosis by ECV304 cells at 37uC without H-kininogen (A–C): biotin-prekallikrein (A), lysosomes/endosomes labeled with LT
Red DND-99 (B), merged images and diphasic contrast (C); with H-kininogen (D–F): biotin-prekallikrein (D), lysosomes/endosomes labeled with LT Red
DND-99 (E), merged images and diphasic contrast (F). Normal endocytosis by ECV304 at 4uC without H-kininogen (G–I): biotin-prekallikrein (G),
lysosomes/endosomes labeled with LT Red DND-99 (H), merged images and diphasic contrast (I); with H-kininogen (J–L): biotin-prekallikrein (J),
lysosomes/endosomes labeled with LT Red DND-99 (K), merged images and diphasic contrast (L).
doi:10.1371/journal.pone.0091280.g001
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kininogen assembly in these cells (Figure 6). Regardless of H-
kininogen treatment (Figures 6A and 6B), almost no prekallikrein
fragments were detected on the cell surfaces. Surprisingly, in the
supernatants of the samples with added H-kininogen, prekallikrein
fragments of 53 kDa and smaller were detected by U691.10
starting at a15 min incubation and increasing in intensity over
time (Figure 6C). Without H-kininogen, only a prekallikrein
fragment of 53 kDa was detected, which also increased in intensity
over time (Figure 6D).
Our results clearly showed prekallikrein cleavage/activation
independently of GAG; nevertheless, in the presence of H-
kininogen assembled on the cell surface through GAG, prekallik-
rein hydrolysis to plasma kallikrein is more specific.
We also analyzed the H-kininogen structure assembled on the
cell surface after the interaction with prekallikrein (Figure 7). In
ECV304 cells (Figure 7A), H-kininogen (120 kDa) cleavage during
prekallikrein activation resulted in bands of 68 kDa, 61 kDa and
47 kDa; the same pattern was previously obtained in HUVECs
[18]. Therefore, in CHO-K1 cells (Figure 7B) and CHO-745 cells
Figure 2. Endocytosis of biotin-prekallikrein by CHO-K1 cells. CHO-K1 cells were grown on cover slips, and the lysosomes/endosomes were
labeled with 0.5 mM LT Red DND-99 in incubation buffer for 20 min at 37uC. They were then treated with or without H-kininogen (100 nM,
unlabelled) for 30 min and then with biotin-prekallikrein (100 nM) for 1 h at 37uC. The cells were incubated with FITC-conjugated streptavidin
(green). Alternatively, after labeling with 0.5 mM LT Red DND-99 at 37uC, the cells were maintained at 4uC and then treated with or without H-
kininogen (100 nM, unlabelled) for 30 min and with biotin-prekallikrein (100 nM) for 1 h at 4uC. Biotin-prekallikrein (green) endocytosis and
intracellular localization are indicated by their colocalization with acidic vesicles previously labeled with LT Red DND-99 (red) and were analyzed by
confocal fluorescence microscopy. Normal endocytosis by CHO-K1 cells at 37uC without H-kininogen (A–C): biotin-prekalikrein (A), lysosomes/
endosomes labeled with LT Red DND-99 (B), merged images and diphasic contrast (C); with H-kininogen (D–F): biotin-prekalikrein (D), lysosomes/
endosomes labeled with LT Red DND-99 (E), merged images and diphasic contrast (F). Normal endocytosis by CHO-K1 cells at 4uC without H-
kininogen (G–I): biotin-prekallikrein (G), lysosomes/endosomes labeled with LT Red DND-99 (H), merged images and diphasic contrast (I); with H-
kininogen (J–L): biotin-prekallikrein (J), lysosomes/endosomes labeled with LT Red DND-99 (K), merged images and diphasic contrast (L).
doi:10.1371/journal.pone.0091280.g002
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(Figure 7C) H-kininogen remained intact at 120 kDa and based on
these results and previous work H-kininogen internalization by
CHO cells is only a possibility [9], [10], [11], [12].
We next examined the possibility that bradykinin free H-
kininogen is also internalized by GAGs. The endocytic compart-
ments of living CHO cells were labeled with LT Green DND-99 at
37uC for 30 min, after which Dylight 659-bradykinin free H-
kininogen (200 nM) was added to the cells. We used confocal
fluorescence images to examine the localization of bradykinin free
H-kininogen at shorter endocytosis times (5–30 min). As seen in
Figure 8, Dylight 659-bradykinin free H-kininogen (red) and LT
Green DND-99 fluorescence did not colocalize within endosomal
acidic vesicles either in CHO-K1 (49.960.002 pixels/cell,
Figure 8A–C) or CHO-745 cells (34.760.001 pixels/cell,
Figure 8D–F).
Discussion
This work shows that the endocytosis of prekallikrein/plasma
kallikrein depends on proteoglycans or GAGs but not on H-
kininogen. These results clearly show that (i) the prekallikrein
Figure 3. Endocytosis of biotin-prekallikrein by CHO-745 cells. CHO-745 cells were grown on cover slips, and the lysosomes/endosomes
were labeled with 0.5 mM LT Red DND-99 in incubation buffer for 20 min at 37uC. Then the cells were treated with or without H-kininogen (100 nM,
unlabelled) for 30 min and with biotin-prekallikrein (100 nM) for 1 h at 37uC. The cells were incubated with FITC-conjugated streptavidin (green).
Alternatively, after labeling with 0.5 mM LT Red DND-99 at 37uC, the cells were maintained at 4uC and treated with or without H-kininogen (100 nM,
unlabelled) for 30 min and with biotin-prekallikrein (100 nM) for 1 h at 4uC. Biotin-prekallikrein (green) endocytosis and intracellular localization are
indicated by colocalization with acidic vesicles previously labeled with LT Red DND-99 (red) and were analyzed by confocal fluorescence microscopy.
Normal endocytosis by CHO-745 cells at 37uC without H-kininogen (A–C): biotin-prekallikrein (A), lysosomes/endosomes labeled with LT Red DND-99
(B), merged images and diphasic contrast (C); with H-kininogen (D–F): biotin-prekallikrein (D), lysosomes/endosomes labeled with LT Red DND-99 (E),
merged images and diphasic contrast (F). Normal endocytosis by CHO-745 cells at 4uC without H-kininogen (G–I): biotin-prekallikrein (G), lysosomes/
endosomes labeled with LT Red DND-99 (H), merged images and diphasic contrast (I); with H-kininogen (J–L): biotin-prekallikrein (J), lysosomes/
endosomes labeled with LT Red DND-99 (K), merged images and diphasic contrast (L).
doi:10.1371/journal.pone.0091280.g003
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interaction with cells is temperature-dependent, (ii) prekallikrein
endocytosis is promoted by proteoglycans or GAGs and (iii)
prekallikrein may interact directly with the cell surface indepen-
dently of H-kininogen but dependent on the GAG composition of
the cell type.
In ECV304 cells (Figure 1), the data support our previous work
performed in HUVECs [18] that showed that prekallikrein
binding occurs in the absence of exogenously applied H-kininogen.
This result suggests a lower affinity specific binding site(s) present
on these cells. At 37uC, using CHO-K1 (Figure 2) and CHO-745
(Figure 3) cells, we showed that proteoglycans or GAGs mediate
biotin-prekallikrein endocytosis. The amounts of heparan sulfate
and chondroitin sulfate produced by CHO-745 cells correspond,
respectively, to 1% and 2.16% of those produced by CHO-K1
cells [35]. Our results strongly suggest that proteoglycans or GAGs
on the cell surface function as additional putative receptors for
prekallikrein and that they direct prekallikrein to acidic endosomal
vesicles, as we showed previously for the H-kininogen interaction
with cells [12]. Fink et al. have shown the prekallikrein/plasma
kallikrein cellular localization in the cytoplasm and on the nuclear
envelope in multiple different progenitor derived cells indicating
specific cellular functions of this enzyme that for instance resides in
the endoplasmic reticulum of particular cells, in addition to its
known function in the blood [21]. The authors attributed to
prekallikrein gene transcription in non-hepatic tissues but our
results show at the first time that prekallikrein/plasma kallikrein
can be internalized by interaction with proteoglycans on cell
surface.
In this work, we analyzed the prekallikrein structure upon its
interaction with the cell surface to investigate whether prekallik-
rein cleavage/activation is influenced by interaction with proteo-
glycans or GAGs or H-kininogen. Prekallikrein hydrolysis was
assessed by detecting the protein bands containing the sequence
C364TTKTSTR371, using the antibody U691.10, which is present
in plasma kallikrein after prekallikrein cleavage/activation [21]. In
ECV304 and CHO-745 cells, a prekallikrein fragment of 53 kDa
was detected that was bound to the cell surface in assembled H-
kininogen complexes. However, in CHO-K1 cells this band was
not detected and also in all cell lines studied without exogenously
applied H-kininogen. In ECV304 cells (Figure 4A) the results are
in agreement with our previous work using HUVECs since a
53 kDa band is detected after exogenous H-kininogen and
prekallikrein assembly on cell surface indicating plasma kallikrein
formation [18]. Considering CHO-745 cells (Figure 6A) a weak
53 kDa band corresponding to prekallikrein/plasma kallikrein
fragment is detected on cell surface with H-kininogen, probably
due to some exogenous H-kininogen bound to other binding sites
different from GAGs on cell surface [8]. Therefore, in CHO-K1
cells (Figure 5A) the 53 kDa band corresponding to prekallikrein
fragment was not detected with exogenously applied H-kininogen
because the ternary complex GAG/H-kininogen/prekallikrein
Figure 4. Prekallikrein structure over time after interaction
with ECV304 cells. H-kininogen (100 nM) was incubated for 1 h with
ECV304 cells, and after removing unbound H-kininogen by aspiration,
prekallikrein (100 nM) was added for 15 min, 30 min, 1 h or 2 h at 37uC.
Alternatively, prekallikrein was added to the cells at different time
points in the absence of assembled H-kininogen. At the end of each
time point, the incubation buffer was collected, and both the
incubation buffer and the cell samples were treated with reducing
sample buffer. Immunoblotting was performed with anti-plasma
kallikrein U-691.10 for detecting plasma kallikrein fragments containing
the sequence C364TTKTSTR371. (A) Cells with H-kininogen: (1) 15 min; (2)
30 min; (3) 1 h; (4) 2 h; (5) plasma kallikrein (0.9 mg); (6) prekallikrein
(1.6 mg); (7) H-kininogen (0.7 mg). (B) Cells without H-kininogen: (1)
15 min; (2) 30 min; (3) 1 h; (4) 2 h; (5) prekallikrein (1.6 mg); (6) plasma
kallikrein (0.9 mg). (C) Incubation buffer with H-kininogen: (1) 15 min; (2)
30 min; (3) 1 h; (4) 2 h; (5) plasma kallikrein (0.9 mg); (6) prekallikrein
(1.6 mg); (7) H-kininogen (0.7 mg). (D) Incubation buffer without H-
kininogen: (1) 15 min; (2) 30 min; (3) 1 h; (4) 2 h; (5) prekallikrein
(1.6 mg); (6) plasma kallikrein (0.9 mg)
doi:10.1371/journal.pone.0091280.g004
Figure 5. Prekallikrein structure over time after interaction
with CHO-K1 cells. H-kininogen (100 nM) was incubated for 30 min
with CHO-K1, and after removing H-kininogen by aspiration, prekallik-
rein (100 nM) was added for 15 min, 30 min, 1 h or 2 h at 37uC.
Alternatively, prekallikrein was added to cells at different time points in
the absence of assembled H-kininogen. At the end of each time point,
the incubation buffer was collected, and both the incubation buffer and
the cell samples were treated with reducing sample buffer. Immuno-
blotting was performed with anti-plasma kallikrein U691.10 for
detecting plasma kallikrein fragments containing the sequence
C364TTKTSTR371. (A) Cells with H-kininogen: (1) 15 min; (2) 30 min; (3)
1 h; (4) 2 h; (5) plasma kallikrein (0.9 mg); (6) prekallikrein (1.6 mg); (7) H-
kininogen (0.7 mg). (B) Cells without H-kininogen: (1) 15 min; (2) 30 min;
(3) 1 h; (4) 2 h; (5) plasma kallikrein (0.9 mg); (6) prekallikrein (1.6 mg). (C)
Incubation buffer with H-kininogen: (1) 15 min; (2) 30 min; (3) 1 h; (4)
2 h; (5) plasma kallikrein (0.9 mg); (6) prekallikrein (1.6 mg); (7) H-
kininogen (0.7 mg). (D) Incubation buffer without H-kininogen: (1)
15 min; (2) 30 min; (3) 1 h; (4) 2 h; (5) plasma kallikrein (0.9 mg); (6)
prekallikrein (1.6 mg)
doi:10.1371/journal.pone.0091280.g005
Figure 6. Prekallikrein structure over time after interaction
with CHO-745 cells. H-kininogen (100 nM) was incubated for 30 min
with CHO-745 cells, and after removing H-kininogen by aspiration,
prekallikrein (100 nM) was added for 15 min, 30 min, 1 h or 2 h at 37uC.
Alternatively, prekallikrein was added to the cells at different time
points in the absence of assembled H-kininogen. At the end of each
time point, the incubation buffer was collected, and both the
incubation buffer and the cell samples were treated with reducing
sample buffer. Immunoblotting was performed with anti-plasma
kallikrein U691.10 for detecting plasma kallikrein fragments containing
the sequence C364TTKTSTR371. (A) Cells with H-kininogen: (1) 15 min; (2)
30 min; (3) 1 h; (4) 2 h; (5) plasma kallikrein (0.9 mg); (6) prekallikrein
(1.6 mg); (7) H-kininogen (0.7 mg). (B) Cells without H-kininogen: (1)
15 min; (2) 30 min; (3) 1 h; (4) 2 h; (5) plasma kallikrein (0.9 mg); (6)
prekallikrein (1.6 mg). (C) Incubation buffer with H-kininogen: (1) 15 min;
(2) 30 min; (3) 1 h; (4) 2 h; (5) plasma kallikrein (0.9 mg); (6) prekallikrein
(1.6 mg); (7) H-kininogen (0.7 mg). (D) Incubation buffer without H-
kininogen: (1) 15 min; (2) 30 min; (3) 1 h; (4) 2 h; (5) plasma kallikrein
(0.9 mg); (6) prekallikrein (1.6 mg)
doi:10.1371/journal.pone.0091280.g006
Plasma Prekallikrein and Cell Surface Interaction
PLOS ONE | www.plosone.org 7 March 2014 | Volume 9 | Issue 3 | e91280
formed on cell surface protected prekallikrein from hydrolysis and
active plasma kallikrein formation was avoided.
The results in the fluid phase (incubation buffer) are interesting
because the 53 kDa fragment is present in both the presence and
absence of H-kininogen. However, in CHO-745 cells prekallikrein
proteolysis occurs at different sites (Figure 6C), likely due to the H-
kininogen bound to sites on cell surface different from GAG and
smaller fragments are also seen for the incubation buffer from
ECV304 treated with and without H-kininogen (Figures 4C and
4D, respectively).
Indeed it is well known that GAGs interact with H-kininogen at
the endothelial cell surface [9], [11], [27], as well as GAGs also
interact with plasma kallikrein modifying its kinetics behavior [36],
[37]. Prekallikrein interaction with cells may generate plasma
kallikrein by proteolytic cleavage and its activity can be analyzed
by H-kininogen structure. In ECV304 cell surface the H-
kininogen fragments of 68 kDa, 61 kDa and 47 kDa (Figure 7A)
suggest a plasma kallikrein formed by one peptide bond cleavage
on prekallikrein (R371-I372) [1]. Therefore, in CHO-K1 (wild type)
we conclude that on cell surface the ternary complex GAG/H-
kininogen/prekallikrein protects prekallikrein from hydrolysis
(Figure 5A) and intact H-kininogen internalization is only
possibility (Figure 7B) [9], [10], [11], [12]. Interestingly in these
cells prekallikrein is internalized more in absence of exogenous H-
kininogen (Figure 2). Considering CHO-745 (mutant deficient in
GAGs) a weak 53 kDa band indicating a plasma kallikrein
fragment can be detected on cell surface (Figure 6A), therefore H-
kininogen remains intact showing none H-kininogen fragment
lower than 120 kDa on cell surface (Figure 7C). Probably the
plasma kallikrein formed on CHO-745 surface is cleaved on heavy
chain because plasma kallikrein fragments of 53 kDa, 44 kDa and
34 kDa are detected in incubation buffer (Figure 6C). In our
previous report [38], we also detected plasma kallikrein bands of
43 kDa, 30 kDa and 20 kDa in activated plasma, which may
correspond to the plasma kallikrein cleaved heavy chain. It has
been described that an intact heavy chain on prekallikrein/plasma
kallikrein structure is very important for the perfect interaction
between prekallikrein and H-kininogen [39] which improves
bradykinin release by plasma kallikrein [40], [41].
Our results clearly show that prekallikrein interaction with
GAGs does not disturb its cleavage/activation (Figure 5D). In fact,
Figure 7. Hydrolysis of cell-associated H-kininogen by mature
plasma kallikrein. H-kininogen (100 nM) in the presence of
incubation buffer was incubated for 1 h or 30 min, respectively, with
ECV304, CHO-K1 and CHO-745 cells at 37uC. After removing H-
kininogen by aspiration, prekallikrein (100 nM) was added for 15 min,
30 min, 1 h or 2 h at 37uC. At the end of each time point, the
incubation buffer was collected, and both the incubation buffer and the
cell samples were treated with reducing sample buffer. Immunoblotting
of the cells was performed with the anti-H-kininogen antibody. (A)
ECV304: (1) 15 min; (2) 30 min; (3) 1 h; (4) 2 h; (5) plasma kallikrein
(0.9 mg); (6) prekallikrein (1.6 mg); (7) H-kininogen (0.7 mg). (B) CHO-K1:
(1) 15 min; (2) 30 min; (3) 1 h; (4) 2 h; (5) plasma kallikrein (0.9 mg); (6)
prekallikrein (1.6 mg); (7) H-kininogen (0.7 mg). (C) CHO-745: (1) 15 min;
(2) 30 min; (3) 1 h; (4) 2 h; (5) plasma kallikrein (0.9 mg); (6) prekallikrein
(1.6 mg); (7) H-kininogen (0.7 mg)
doi:10.1371/journal.pone.0091280.g007
Figure 8. Endocytosis of fluorescent Dylight 659-bradykinin free H-kininogen by CHO cells. CHO-K1 and CHO-745 cells were grown on
cover slips, and the lysosomes/endosomes were labeled with 0.5 mM LT Green in Ham F-12 serum-free medium containing 50.0 mM Zn2+ for 20 min
at 37uC and analyzed by confocal fluorescence microscopy. Dylight 659-bradykinin free H-kininogen (200 nM, red) endocytosis and intracellular
localization are indicated by the colocalization with acidic vesicles labeled with LT Green. Normal endocytosis by CHO-K1: (A) LT Green; (B) Dylight
659- bradykinin free H-kininogen; (C) merged images and diphasic contrast. Normal endocytosis by CHO-745: (D) LT Green; (F) Dylight 659- bradykinin
free H-kininogen; (G) merged images and diphasic contrast.
doi:10.1371/journal.pone.0091280.g008
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H-kininogen bound to GAG may modulate prekallikrein cleav-
age/activation as a control mechanism of prekallikrein/plasma
kallikrein activity (Figures 5A and 5C). Moreover, Renne´ et al.
have shown that bradykinin formation is controlled by H-
kininogen binding to and detachment from GAGs at the
endothelial cells [25].
Since H-kininogen is cleaved on cell surface releasing brady-
kinin [18], [19] the bradykinin free H-kininogen interaction with
cell surface was also examined and the results (Figure 8) show that
neither in presence (CHO-K1) nor absence (CHO-745) of GAGs
bradykinin free H-kininogen endocytosis is detected suggesting
that mature bradykinin free H-kininogen remains outside the cells
where it exerts its regulation of angiogenesis [42].
Our results indicate that plasma kallikrein proteolytic balance of
H-kininogen/bradykinin free H-kininogen forms is controlled by
GAGs modulating the production of bradykinin at endothelial cell
surface [18], [25]. GAGs may promote this control by two
different ways controlling either the proteolytic activity of the
ternary complex GAG/plasma kallikrein/H-kininogen (Figures 5,
6, 7 and 8) or the cellular compartmentalization of kallikrein-kinin
system proteins via endocytosis (Figures 2 and 3). The prekallik-
rein/plasma kallikrein endocytosis mediated by proteoglycans or
GAGs may explain plasma kallikrein localization to the connective
tissue-type mast cells in the mammary gland and other tissues [21],
[2].
In conclusion, our experiments analyzing prekallikrein after
interactions with the cell surface either in the presence or absence
of exogenously applied H-kininogen show that prekallikrein
endocytosis and proteolysis are mechanisms that contribute
independently to the control of plasma kallikrein activity and are
mediated by proteoglycans.
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